Comparison
Cagrilintide vs. GHRP-2
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
1415456-99-3
158861-67-7
Molecular weight
4253.7 g/mol
817.93 g/mol
Half-life
168 h
0.5 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYD-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
4
of which in humans
3
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1